Press release
Lewy Body Dementia Market to Reach USD 9.4 Billion by 2034
Lewy Body Dementia
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71909
With aging populations and rising awareness, the LBD market is expanding. Current management relies on cholinesterase inhibitors, antipsychotics, Parkinson's medications, and supportive care, but safety concerns and limited efficacy create an urgent need for new therapies. Advances in neuroimaging, biomarker testing, and digital health monitoring are reshaping early detection and management.
Market Overview
• Market Size (2024): USD 5.2 billion
• Forecast (2034): USD 9.4 billion
• CAGR (2025-2034): 6.0%
Growth is driven by rising dementia prevalence, improved diagnosis, and pipeline therapies targeting alpha-synuclein and neuroinflammation.
Key Highlights:
• LBD affects ~1.4 million people in the U.S. alone, with millions more worldwide.
• Early misdiagnosis as Alzheimer's or Parkinson's remains common.
• Cholinesterase inhibitors (donepezil, rivastigmine) are widely prescribed.
• Digital biomarkers and AI-powered neurocognitive testing gaining adoption.
Segmentation Analysis
By Product Type:
• Pharmacological Therapies
o Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine)
o Parkinsonian Agents (Levodopa, Carbidopa)
o Antipsychotics (Quetiapine, Clozapine - cautious use due to sensitivity)
o Antidepressants (SSRIs, SNRIs for mood symptoms)
o Pipeline Therapies (alpha-synuclein antibodies, neuroprotective drugs)
• Non-Pharmacological Interventions
o Cognitive Behavioral Therapy (CBT)
o Physical & Occupational Therapy
o Lifestyle and Supportive Care Programs
• Diagnostics & Digital Tools
o PET & MRI Imaging
o CSF and Blood Biomarkers
o Digital Cognitive Assessment Tools
By Platform:
• Small Molecules (cholinesterase inhibitors, antipsychotics)
• Biologics (immunotherapies under research)
• Digital Health Tools
By Technology:
• AI-Powered Neurocognitive Testing
• Biomarker-Based Diagnostics
• Digital Therapeutics & Remote Monitoring
By End Use:
• Hospitals & Neurology Clinics
• Memory Care Centers
• Home Care Settings
• Research Institutes
By Application:
• Early-Stage Lewy Body Dementia
• Moderate-to-Severe LBD
• Clinical Research
Segmentation Summary:
Pharmacological therapies dominate, but digital and biomarker-based diagnostics are rapidly growing. Pipeline biologics targeting alpha-synuclein aggregation represent future breakthroughs.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71909/lewy-body-dementia-market
Regional Analysis
North America
• ~44% share in 2024.
• Strong diagnostic adoption, advanced dementia care infrastructure.
• FDA approvals of symptomatic therapies and biomarker-driven research.
Europe
• ~29% share.
• Germany, UK, and France lead in dementia research and integrated care models.
• EMA fostering innovation in neurodegenerative drug pipelines.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.2%.
• Rising dementia burden in Japan, China, and India.
• Expanding memory clinics and digital health adoption.
Middle East & Africa
• Smaller market but growing with aging demographics.
• Limited specialized dementia infrastructure.
Latin America
• Brazil and Mexico driving demand.
• Increasing access to generics and caregiver support programs.
Regional Summary:
North America and Europe dominate due to infrastructure and R&D pipelines, while Asia-Pacific grows fastest due to rapid demographic aging and healthcare expansion.
Market Dynamics
Key Growth Drivers:
• Rising global dementia prevalence.
• Improved diagnosis with biomarkers and imaging.
• Pipeline therapies targeting alpha-synuclein and neuroinflammation.
• Digital health solutions for remote cognitive monitoring.
Key Challenges:
• Misdiagnosis with Alzheimer's and Parkinson's disease.
• Lack of disease-modifying therapies.
• High care costs and caregiver burden.
• Limited access in low-income regions.
Latest Trends:
• Alpha-synuclein immunotherapies under clinical trials.
• AI-based cognitive assessments for early detection.
• Growth of digital therapeutics and caregiver support apps.
• Integration of multi-modal care: drug + therapy + digital health.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71909
Competitor Analysis
Major Players in the Market:
• Novartis AG (Rivastigmine)
• Eisai Co., Ltd. (Donepezil - with Pfizer Inc.)
• Johnson & Johnson
• GlaxoSmithKline plc
• Eli Lilly and Company (neurodegenerative pipeline)
• Biogen Inc. (anti-amyloid and alpha-synuclein R&D)
• Roche Holding AG (diagnostics & biomarkers)
• AbbVie Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Cogstate Ltd. (digital cognitive testing tools)
Competitive Summary:
Novartis and Eisai dominate symptomatic therapy, while Biogen, Roche, and Eli Lilly lead neurodegenerative R&D. Cogstate and digital health firms pioneer neurocognitive testing. Competition centers on pipeline biologics, AI diagnostics, and integrated dementia care models.
Conclusion
The Lewy Body Dementia (LBD) Market, valued at USD 5.2 billion in 2024, is projected to reach USD 9.4 billion by 2034, growing at a CAGR of 6.0%. Expanding diagnosis, digital health adoption, and pipeline therapies will continue to shape the market.
Key Takeaways:
• Cholinesterase inhibitors remain standard of care, but biologics are emerging.
• North America and Europe dominate, while Asia-Pacific grows fastest.
• AI-based cognitive diagnostics and digital therapeutics gaining traction.
• Integrated multimodal care will define future LBD management.
The next decade will transform LBD care from symptom-focused management to precision-driven, biomarker-guided, and digitally integrated dementia care, creating opportunities for pharma, biotech, and digital health innovators.
This report is also available in the following languages : Japanese (レビー小体型認知症市場), Korean (루이소체 치매 시장), Chinese (路易体痴呆症市场), French (Marché de la démence à corps de Lewy), German (Markt für Lewy-Body-Demenz), and Italian (Mercato della demenza da corpi di Lewy), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71909/lewy-body-dementia-market#request-a-sample
Our More Reports:
Single Nucleotide Polymorphism (SNP) Genotyping Market
https://exactitudeconsultancy.com/reports/72390/single-nucleotide-polymorphism-snp-genotyping-market
Digital Psychotherapeutics Market
https://exactitudeconsultancy.com/reports/72389/digital-psychotherapeutics-market
Whole Genome Sequencing Market
https://exactitudeconsultancy.com/reports/72388/whole-genome-sequencing-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lewy Body Dementia Market to Reach USD 9.4 Billion by 2034 here
News-ID: 4179609 • Views: …
More Releases from Exactitude Consultancy
Vacuum Insulated Pipe Market Projected to Reach USD 2.36 Billion by 2034
Introduction: A Market Built on Cryogenic Efficiency and Innovation
The global Vacuum Insulated Pipe (VIP) market is witnessing a steady surge driven by the expanding cryogenic industry, increased liquefied natural gas (LNG) trade, and rising demand for efficient liquid gas transportation systems. These specialized double-wall pipes, engineered with high vacuum insulation between inner and outer layers, have become indispensable in industries handling cryogenic fluids such as liquid nitrogen, oxygen, argon, and…
Solar PV Mounting Systems Market is Expected to Reach USD 31.7 Billion by 2034
Introduction: Powering the Next Decade of Solar Expansion
The Solar PV Mounting Systems Market is emerging as a crucial pillar in the clean energy revolution, enabling efficient, cost-effective, and durable installations of photovoltaic (PV) modules across rooftops, open fields, and floating structures. As the world accelerates toward carbon neutrality, the demand for robust, modular, and adaptable mounting systems has intensified across residential, commercial, and utility-scale solar projects.
Download Full PDF Sample Copy…
Tall Oil Fatty Acid Market projected to reach USD 2.21 billion by 2034
Introduction: A Sustainable Feedstock Powering the Future of Bio-based Chemicals
The Tall Oil Fatty Acid (TOFA) Market is gaining strong traction as industries increasingly shift toward renewable, sustainable, and bio-based chemical alternatives. Derived as a byproduct from the kraft pulping process of pine wood, TOFA has become a vital raw material in the production of alkyd resins, dimer acids, lubricants, coatings, and adhesives. Its unique composition-rich in oleic and linoleic acids-makes…
Lithium-Ion Battery Recycling Market Projected to Reach USD 27.3 Billion by 2034
Introduction: Powering the Circular Energy Transition
As the world accelerates toward electrification and clean energy, the demand for lithium-ion batteries has skyrocketed-fueling everything from electric vehicles (EVs) to smartphones and grid storage systems. However, this exponential growth brings with it an urgent environmental challenge: how to sustainably manage end-of-life batteries.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/25354
The Lithium-Ion Battery Recycling Market has emerged as a cornerstone of the global…
More Releases for Lewy
Lewy Body Dementia Market Forecast 2025-2034: Comprehensive Analysis And Growth …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Projected Growth of the Lewy Body Dementia Market?
In recent times, the market size for Lewy body dementia has witnessed substantial growth. It is projected to increase from $1.12 billion in 2024 to $1.21 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. The historic growth…
Lewy Body Disease Pipeline: 10+ Innovators Advancing Disease-Modifying and Sympt …
Lewy Body Disease (LBD), including dementia with Lewy bodies and Parkinson's disease dementia, is a complex neurodegenerative condition attracting the attention of over 10 key companies such as Cognition Therapeutics, Eli Lilly and Company, Athira Pharma, and NLS Pharmaceutics. The LBD pipeline features therapies targeting alpha-synuclein, neuroprotective agents, and symptomatic treatments that address cognition, motor symptoms, and neuropsychiatric complications. With no approved disease-modifying treatment, this pipeline represents a vital frontier…
Lewy Body Dementia Treatment Market Challenges: Growth, Share, Value, Trends and …
Lewy Body Dementia Treatment Market Size And Forecast by 2031
The LBD Therapy Market is expanding rapidly, driven by increasing consumer demand, technological advancements, and industry-wide innovation. According to top market research firms, businesses in the Neurodegenerative Disorder Treatment Market are prioritizing digital transformation, product development, and data-driven decision-making to stay competitive. With rising investments in automation and efficiency, the Dementia Care Market is evolving to meet changing customer preferences.…
Lewy Body Dementia Treatment Market Focuses on Advancements in Diagnosis and The …
Global Lewy Body Dementia Treatment Market, By Drug Type (Cholinesterase Inhibitors, Antipsychotic Drugs, Antidepressants, Benzodiazepine, and Modafinil), Application Type (Parkinson's Disease and Alzheimer's Disease), Mode of Purchase (Prescription and Over the Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies and Others) - Industry Trends and Forecast to 2031.
Data Bridge Market Research analyses that the Global Lewy Body Dementia Treatment Market which was USD 5.66 Billion in 2023…
Lewy Body Dementia Treatment Market Analysis, Trends & Forecast 2024-2033 | Grow …
The lewy body dementia treatment market size has grown strongly in recent years. It will grow from $4.14 billion in 2023 to $4.41 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to supportive care and family education, regulatory approvals and guideline, multidisciplinary care approaches, psychosocial and behavioral interventions, multidisciplinary care approaches..
The lewy body dementia treatment…
Lewy Body Dementia Treatment Market to see Rapid Growth by 2029
The Lewy Body Dementia Treatment Market size is expected to grow at an annual average of CAGR 4% during the forecast period (2023-2029). Lewy Body Dementia (LBD) affects people mostly aged 50 years and above. It accounts for about 1-2% of all the cases of dementia. Lewy body is also projected to be found in other neurological disorders such as Parkinson's disease and Alzheimer's disease. Furthermore, underdiagnosis and late…
